ORMP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oramed Pharmaceuticals Inc (ORMP) is not a good buy for a beginner, long-term investor at this time. The stock lacks positive catalysts, has weak financial performance, and shows no strong trading signals or upward momentum. The technical indicators and options data suggest a neutral to bearish sentiment, and the company's financials indicate significant declines in net income and EPS. Given the user's impatience and preference for long-term investments, this stock does not align with their goals.
The MACD histogram is negative (-0.0144) and contracting, RSI is neutral at 52.072, and moving averages are converging, indicating no clear trend. Support and resistance levels suggest limited upward potential, with pivot at 3.426 and resistance at 3.583. Candlestick pattern analysis predicts a 100% chance of a -0.43% drop in the next day, -1.57% in the next week, and -8.99% in the next month.
NULL identified. No recent news, no significant hedge fund or insider trading activity, and no recent congress trading data.
Weak financial performance with a 198.23% YoY drop in net income and a 200% YoY drop in EPS. No positive trading signals from AI Stock Picker or SwingMax. Technical indicators and candlestick patterns suggest a bearish trend in the short to medium term.
In Q4 2025, revenue remained at 0 with no growth. Net income dropped significantly by -198.23% YoY to $10,009,000, and EPS fell by -200% YoY to 0.25. Gross margin increased to 0.65 but had no YoY growth. Overall, financial performance is weak and shows no signs of improvement.
No recent analyst ratings or price target changes available for ORMP.
